|
Name |
Dodecanamide
|
Molecular Formula | C12H25NO | |
IUPAC Name* |
dodecanamide
|
|
SMILES |
CCCCCCCCCCCC(=O)N
|
|
InChI |
InChI=1S/C12H25NO/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h2-11H2,1H3,(H2,13,14)
|
|
InChIKey |
ILRSCQWREDREME-UHFFFAOYSA-N
|
|
Synonyms |
DODECANAMIDE; Lauramide; 1120-16-7; Dodecylamide; Lauric amide; Lauryl amide; Dodecamide; Amide KK; Lauric acid amide; Dodecanoic acid amide; NSC 889; NSC-889; 3BD22052MO; NSC-26630; EINECS 214-298-7; NSC 26630; Lauroylamide; n-dodecanamide; UNII-3BD22052MO; Dodecylacid amide; Diamide Y; LAURAMIDE [INCI]; SCHEMBL42192; NSC889; DTXSID5022146; SCHEMBL11355406; CHEBI:34726; BAA12016; NSC26630; ZINC1587675; LMFA08010001; MFCD00025532; AKOS006228958; FS-4114; DB-041030; CS-0206349; FT-0625579; L0077; D91239; A925590; Q27116246
|
|
CAS | 1120-16-7 | |
PubChem CID | 14256 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 199.33 | ALogp: | 3.5 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 14 | QED Weighted: | 0.528 |
Caco-2 Permeability: | -4.683 | MDCK Permeability: | 0.00002620 |
Pgp-inhibitor: | 0.016 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.847 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.992 | Plasma Protein Binding (PPB): | 95.44% |
Volume Distribution (VD): | 0.696 | Fu: | 4.28% |
CYP1A2-inhibitor: | 0.858 | CYP1A2-substrate: | 0.422 |
CYP2C19-inhibitor: | 0.384 | CYP2C19-substrate: | 0.068 |
CYP2C9-inhibitor: | 0.317 | CYP2C9-substrate: | 0.804 |
CYP2D6-inhibitor: | 0.019 | CYP2D6-substrate: | 0.108 |
CYP3A4-inhibitor: | 0.09 | CYP3A4-substrate: | 0.062 |
Clearance (CL): | 6.235 | Half-life (T1/2): | 0.188 |
hERG Blockers: | 0.16 | Human Hepatotoxicity (H-HT): | 0.028 |
Drug-inuced Liver Injury (DILI): | 0.044 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.025 | Maximum Recommended Daily Dose: | 0.014 |
Skin Sensitization: | 0.805 | Carcinogencity: | 0.074 |
Eye Corrosion: | 0.13 | Eye Irritation: | 0.936 |
Respiratory Toxicity: | 0.046 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000722 | 0.846 | D05ATI | 0.536 | ||||
ENC000102 | 0.773 | D07ILQ | 0.523 | ||||
ENC000399 | 0.773 | D0O1PH | 0.500 | ||||
ENC000688 | 0.765 | D0Z5SM | 0.476 | ||||
ENC000260 | 0.723 | D0Z5BC | 0.442 | ||||
ENC000556 | 0.705 | D0XN8C | 0.441 | ||||
ENC000270 | 0.705 | D03ZJE | 0.420 | ||||
ENC002845 | 0.698 | D0Y8DP | 0.404 | ||||
ENC000687 | 0.692 | D05QNO | 0.403 | ||||
ENC001646 | 0.684 | D0O1TC | 0.378 |